Results 81 to 90 of about 17,592 (206)

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, Volume 159, Issue 1, Page 244-256, 1 July 2026.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

, 2018
Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Mara ...
Gostkorzewicz J, Galve-Calvo E, Pérez-Mitru A, González-Haba E, Martínez I   +4 more
core  

Does CDKN2A Loss Predict Palbociclib Benefit?

, 2015
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, her2 ...
R.P. Adams, J. Gao, S.M. Swain
core   +1 more source

2‐Hydroxyisobutyrylation and Phosphorylation Crosstalk Guides Metastasis Prediction and Immunotherapy in Esophageal Squamous Cell Carcinoma

MedComm, Volume 7, Issue 7, July 2026.
This study deciphers the functional crosstalk between 2‐hydroxyisobutyrylation (Khib) and phosphorylation in driving esophageal squamous cell carcinoma (ESCC) metastasis. Through multi‐omics and machine learning, we developed a plasma protein signature for noninvasive detection of lymph node metastasis.
Junyi Li, Shujun Li, Xiaomei Yu, Qier Mu, Maowen Luo, Yuzhen Wang, Zhichao Liu, Chengwei Gu, Jiaxi Chen, Wangcheng He, Tong Yang, Yan He, Xiaoya Pei, Mao Lin, Zhigang Li, Jun Liu, Baosheng Zhao, Fan Zhang, Jinbao Liu, Bin Li, Wenwen Xu   +20 more
wiley   +1 more source

Altering distribution profile of palbociclib by its prodrugs

Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is currently used clinically for treating hormone receptor-positive and human epidermal growth factor receptor 2 negative breast cancer.
Elmquist, William, Huttunen, Kristiina, Järvinen, Juulia, Leppänen, Jukka, Jalkanen, Aaro J., Laitinen, Tuomo, Adla, Santosh, Rautio, Jarkko, Montaser, Ahmed, Lehtonen, Marko, Vellonen, Kati-Sisko, Timonen, Juri Mikael   +11 more
core   +1 more source

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin, Yuhan Zhang, Yuantai Zhu, Zhiyuan Zhang, Chaoji Shi   +4 more
wiley   +1 more source

A Constellation of Fluorescent Biosensors to Illuminate the Galaxy of Protein Kinases

ChemBioChem, Volume 27, Issue 11, 15 June 2026.
Protein kinases (PKs) are enzymes that catalyze phosphorylation of protein substrates involved in a wide variety of biological signalling pathways. This review describes the different families and mechanisms of action and regulation of protein kinases, together with the different classes of fluorescent biosensors that have been engineered and ...
Timothe Abbura, May C. Morris
wiley   +1 more source

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis.

PLoS ONE
Breast cancer (BC) cells have a high risk of metastasis due to epithelial-mesenchymal transition (EMT). Palbociclib (CDK4/6 inhibitor) is an approved drug for BC treatment.
Xiaogang Li, Chao Niu, Guoqiang Yi, Yuan Zhang, Wendi Jin, Zhiping Zhang, Wanfu Zhang, Bo Li   +7 more
doaj   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, Volume 13, Issue 35, 24 June 2026.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source